Fructosamine Reference Range Established for Brazil
|
By LabMedica International staff writers Posted on 14 Jan 2019 |

Image: The AU 5800 automatic analyzer (Photo courtesy of Beckman Coulter).
Traditional markers used in diabetes diagnosis and monitoring include fasting plasma glucose (FPG), two-hour plasma glucose (2-hPG) measured during the oral glucose tolerance test (OGTT), and glycated hemoglobin (HbA1c) levels.
The fructosamine test is used in the monitoring of diabetes mellitus, particularly in cases with restrictions on the use of glycated hemoglobin, mainly in the setting of altered red blood cell lifespan and interference by hemoglobin variants. It could also provide additional information on shorter-term glycemic control.
Scientists at the Federal University of Minas Gerais, (Belo Horizonte, Brazil) collected blood samples from 2,288, that were part of a comprehensive study and available for fructosamine testing. The team excluded from the study individuals with a previous history of diabetes (n = 161), with FPG ≥ 5.6 mmol/L (100 mg/dL) and/or 2-hPG ≥ 7.8 mmol/L (140 mg/dL) and/or HbA1c ≥ 38.8 mmol/mol, (5.7%). They also excluded individuals with microalbuminuria ≥ 20 μg/min and creatinine> 114.9 µmol/L (1.3 mg/dL).
Samples were collected after a 12-h fasting period. The OGTT was conducted in all participants included in the present study. Samples were stored at −80 °C. Serum fructosamine levels were determined by the colorimetric nitroblue tetrazolium method in an AU 5800 automatic analyzer. The scientists proposed that the reference interval should be 186 to 248 μmol/L for women and 196 to 269 μmol/L for men. Fructosamine levels were higher in men than in women and in the non-white population and had a negative correlation with the body mass index.
The authors concluded that their study represents the first effort to establish a reference range for fructosamine levels in the Brazilian population. The report, which used the ELSA-Brazil baseline as a source of data, might contribute to future work on the diagnosis and monitoring of diabetes mellitus (DM), especially in situations when HbA1c and OGTT cannot be used. The study was published in the January 2019 issue of the journal Practical Laboratory Medicine.
Related Links:
Federal University of Minas Gerais
The fructosamine test is used in the monitoring of diabetes mellitus, particularly in cases with restrictions on the use of glycated hemoglobin, mainly in the setting of altered red blood cell lifespan and interference by hemoglobin variants. It could also provide additional information on shorter-term glycemic control.
Scientists at the Federal University of Minas Gerais, (Belo Horizonte, Brazil) collected blood samples from 2,288, that were part of a comprehensive study and available for fructosamine testing. The team excluded from the study individuals with a previous history of diabetes (n = 161), with FPG ≥ 5.6 mmol/L (100 mg/dL) and/or 2-hPG ≥ 7.8 mmol/L (140 mg/dL) and/or HbA1c ≥ 38.8 mmol/mol, (5.7%). They also excluded individuals with microalbuminuria ≥ 20 μg/min and creatinine> 114.9 µmol/L (1.3 mg/dL).
Samples were collected after a 12-h fasting period. The OGTT was conducted in all participants included in the present study. Samples were stored at −80 °C. Serum fructosamine levels were determined by the colorimetric nitroblue tetrazolium method in an AU 5800 automatic analyzer. The scientists proposed that the reference interval should be 186 to 248 μmol/L for women and 196 to 269 μmol/L for men. Fructosamine levels were higher in men than in women and in the non-white population and had a negative correlation with the body mass index.
The authors concluded that their study represents the first effort to establish a reference range for fructosamine levels in the Brazilian population. The report, which used the ELSA-Brazil baseline as a source of data, might contribute to future work on the diagnosis and monitoring of diabetes mellitus (DM), especially in situations when HbA1c and OGTT cannot be used. The study was published in the January 2019 issue of the journal Practical Laboratory Medicine.
Related Links:
Federal University of Minas Gerais
Latest Clinical Chem. News
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
- Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
- Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Channels
Molecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








